Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PPD's Lee Babiss On Virtual R&D In China: An Interview With PharmAsia News (Part 2 Of 2)

This article was originally published in PharmAsia News

Executive Summary

Lee Babiss left his position as president of pharmaceutical research at Roche to become the executive vice president of global laboratory services at the Wilmington, North Carolina-based contract research organization PPD. In part one of an interview with PharmAsia News, Babiss spoke about the evolving relationships between pharmaceutical firms and CROs, including end-to-end virtualization of R&D (PharmAsia News, April 6, 2010).

You may also be interested in...

PPD's Lee Babiss On Virtual R&D In China: An Interview With PharmAsia News (Part 1 Of 2)

Lee Babiss left Roche, one of the world's largest pharmaceutical companies, for a contract research organization position in part because his days as president of drug research were filled less with driving research projects forward and more with containing his group's costs, a reflection of the current state of R&D productivity at major pharmaceutical firms.

China To Implement New Regulations For Patent Law; Companies Should Set Up Inventor Reward Policy To Prepare For Changes

SHANGHAI - China's State Council recently approved new implementation regulations for the country's Patent law, which clarifies procedural issues in line with new changes to the patent law that took effect last year

Roche Hits A Wall With Its Tarceva Patent Claims In India; Novartis Moves Supreme Court For Glivec Rights

MUMBAI - For the two Swiss drug giants Novartis and Roche, there was much action at India's Supreme Court Aug. 28 as they separately continued the fight to safeguard patents on their life-saving oncology drugs steadfastly challenged by health activists and generic drug manufacturers alike in India




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts